Medicus Pharma to Ring Nasdaq Opening Bell on January 22, 2026, Celebrating One-Year Anniversary
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Source: Globenewswire
- Anniversary Celebration: Medicus Pharma will ring the Nasdaq Opening Bell on January 22, 2026, at the Nasdaq MarketSite in Times Square, New York, marking its one-year anniversary as a publicly listed company and highlighting its steady growth in the capital markets.
- Significant Clinical Progress: The company is advancing two key therapeutic assets, SkinJect targeting basal cell carcinoma with an estimated $2 billion market opportunity, and Teverelix for high cardiovascular risk prostate cancer patients, representing a combined market potential of $6 billion, showcasing its strategic positioning in precision medicine.
- Clinical Trial Advancements: Medicus has successfully enrolled 90 patients in the Phase 2 clinical trial for SkinJect in the U.S., with topline results expected in Q1 2026, which will lay the groundwork for future partnership opportunities and enhance the company's influence in the biopharmaceutical sector.
- Strategic Collaboration Expansion: The company has entered a non-binding letter of intent with Reliant AI Inc. to develop an AI-driven clinical data analytics platform aimed at improving capital-efficient clinical development, expected to support an upcoming Teverelix clinical study planned for 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDCX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDCX
Wall Street analysts forecast MDCX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDCX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.250
Low
12.00
Averages
12.00
High
12.00
Current: 1.250
Low
12.00
Averages
12.00
High
12.00
About MDCX
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medicus Pharma to Ring Nasdaq Opening Bell on January 22, 2026, Celebrating One-Year Anniversary
- Anniversary Celebration: Medicus Pharma will ring the Nasdaq Opening Bell on January 22, 2026, at the Nasdaq MarketSite in Times Square, New York, marking its one-year anniversary as a publicly listed company and highlighting its steady growth in the capital markets.
- Significant Clinical Progress: The company is advancing two key therapeutic assets, SkinJect targeting basal cell carcinoma with an estimated $2 billion market opportunity, and Teverelix for high cardiovascular risk prostate cancer patients, representing a combined market potential of $6 billion, showcasing its strategic positioning in precision medicine.
- Clinical Trial Advancements: Medicus has successfully enrolled 90 patients in the Phase 2 clinical trial for SkinJect in the U.S., with topline results expected in Q1 2026, which will lay the groundwork for future partnership opportunities and enhance the company's influence in the biopharmaceutical sector.
- Strategic Collaboration Expansion: The company has entered a non-binding letter of intent with Reliant AI Inc. to develop an AI-driven clinical data analytics platform aimed at improving capital-efficient clinical development, expected to support an upcoming Teverelix clinical study planned for 2026.
Continue Reading
Medicus Pharma Rings Nasdaq Opening Bell to Celebrate One-Year Listing Anniversary
- Anniversary Celebration: Medicus Pharma will ring the Nasdaq Opening Bell on January 22, 2026, in Times Square, New York, marking its one-year anniversary as a public company, reflecting its stability and growth potential in the capital markets.
- Clinical Development Progress: The company is focused on advancing key therapeutic assets like SkinJect and Teverelix, with SkinJect targeting a $2 billion market opportunity for basal cell carcinoma and Teverelix addressing high cardiovascular risk in prostate cancer patients, collectively representing a $6 billion commercial value.
- Clinical Trial Results: The Phase 2 trial for SkinJect is nearing completion of patient enrollment, with topline results expected in Q1 2026, potentially creating partnership opportunities and further enhancing the company's influence in the biotech sector.
- Strategic Collaboration and Expansion: The partnership with the Gorlin Syndrome Alliance aims to provide expanded access to SkinJect for patients with multiple basal cell carcinomas, expected to gather crucial safety and tolerability data, thereby strengthening the company's market position in rare diseases.
Continue Reading